Department of Medicine Medical College of Wisconsin, Blood Research Institute, Versiti, Milwaukee, WI.
Department of Medicine and.
Blood. 2022 Aug 25;140(8):809-814. doi: 10.1182/blood.2021014527.
Coronavirus disease-19 (COVID-19) includes a thromboinflammatory syndrome that may manifest with microvascular and macrovascular thrombosis. Patients with COVID-19 have a higher incidence of venous thromboembolism than other hospitalized patients. Three randomized control trials suggesting benefit of therapeutic heparin in hospitalized noncritically ill patients with COVID-19 have led to conditional guideline recommendations for this treatment. By contrast, prophylactic-dose heparin is recommended for critically ill patients. Unprecedented collaboration and rapidly funded research have improved care of hospitalized patients with COVID-19.
新型冠状病毒病-19（COVID-19）包括一种血栓炎症综合征，可能表现为微血管和大血管血栓形成。与其他住院患者相比，COVID-19 患者静脉血栓栓塞的发生率更高。三项随机对照试验表明，治疗用肝素对 COVID-19 住院非危重症患者有益，因此为该治疗方法提供了有条件的指南建议。相比之下，建议对危重症患者使用预防性剂量肝素。前所未有的合作和快速资助的研究改善了 COVID-19 住院患者的护理。
